title: The TP53 gene polymorphisms and survival of sporadic breast cancer patients.
abstract: The TP53 gene polymorphisms, Arg72Pro and PIN3 (+16 bp), can have prognostic and predictive value in different cancers including breast cancer. The aim of the present study is to investigate a potential association between different genotypes of these polymorphisms and clinicopathological variables with survival of breast cancer patients in Croatian population. Ninety-four women with sporadic breast cancer were retrospectively analyzed. Median follow-up period was 67.9 months. The effects of basic clinical and histopathological characteristics of tumor on survival were tested by Cox's proportional hazards regression analysis. The TNM stage was associated with overall survival by Kaplan-Meier analysis, univariate, and multivariate Cox's proportional hazards regression analysis, while grade was associated with survival by Kaplan-Meier analysis and univariate Cox's proportional hazards regression analysis. Different genotypes of the Arg72Pro and PIN3 (+16 bp) polymorphisms had no significant impact on survival in breast cancer patients. However, in subgroup of patients treated with chemotherapy without anthracycline, the A2A2 genotype of the PIN3 (+16 bp) polymorphism was associated with poorer overall survival than other genotypes by Kaplan-Meier analysis (P = 0.048). The TP53 polymorphisms, Arg72Pro and PIN3 (+16 bp), had no impact on survival in unselected sporadic breast cancer patients in Croatian population. However, the results support the role of the A2A2 genotype of the PIN3 (+16 bp) polymorphism as a marker for identification of patients that may benefit from anthracycline-containing chemotherapy.
authors.affiliation: Department of Oncology, Clinical Hospital Centre Zagreb, Kišpatićeva 12, 10 000 Zagreb, Croatia. vesna.bisof@zg.t-com.hr
authors.forename: V
authors.initials: V
authors.lastname: Bišof
authors.forename: M Peričić
authors.initials: MP
authors.lastname: Salihović
authors.forename: N Smolej
authors.initials: NS
authors.lastname: Narančić
authors.forename: T
authors.initials: T
authors.lastname: Skarić-Jurić
authors.forename: J
authors.initials: J
authors.lastname: Jakić-Razumović
authors.forename: B
authors.initials: B
authors.lastname: Janićijević
authors.forename: P
authors.initials: P
authors.lastname: Rudan
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000235:genetics / Q000401:mortality / Q000473:pathology; D018275:Carcinoma, Lobular / Q000235:genetics / Q000401:mortality / Q000473:pathology; D018276:Carcinoma, Medullary / Q000235:genetics / Q000401:mortality / Q000473:pathology; D017523:Croatia; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000235:genetics / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic / Q000235:genetics*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53